
Ascelia Pharma (Q3 review) - Partnering in focus ahead

Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises. We make some near term changes to our estimates but largely reiterate our view.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ascelia Pharma (Q3 review) - Partnering in focus ahead